CYP17A1 and posterior cortical atrophy: Since abiraterone, a commonly used 17α-hydroxylase, 17,20-lyase (CYP17A1) inhibitor, is transported to the prostate via (ubiquitous) SLCO, this raises the possibility of the successful chemical treatment of PCa by the targeted drug delivery.